Key Highlights
- TwoStep Therapeutics launched with $6.5M seed funding led by NFX.
- Focus on developing targeted therapies for solid tumors.
- Utilizes unique polyspecific integrin-binding peptide (PIP) technology.
- Broad applicability to a wide range of tumor types and patient populations.
- Founded by leading scientists from Stanford University.
Source: Business Wire
Notable Quotes
- “Our initial focus at TwoStep is to couple our tumor-targeting technology with clinically-validated payloads, which has the potential to extend the benefits of paradigm-shifting therapies to a greater number of patients.” — Caitlyn Miller, PhD, CEO and co-founder at TwoStep Therapeutics
- “Imagine one system that can target most solid tumors and deliver the exact treatment needed. It could mean many lives saved with one core technology platform.” — Omri Amirav-Drory, PhD, General Partner at NFX
- “In its compact form, PIP is a synthetic, ultra-stable peptide that has been engineered to localize and penetrate tumors – ideal properties for broad targeted therapy applications.” — Jennifer Cochran, PhD, co-founder at TwoStep Therapeutics
SoHC's Take
TwoStep Therapeutics is set to make a significant impact in the oncology field with its innovative approach to solid tumor treatment. By leveraging its unique polyspecific integrin-binding peptide (PIP) technology, TwoStep aims to overcome the challenges of targeting a broad range of solid tumors. The successful $6.5 million seed funding round, backed by prominent investors such as NFX and others, highlights the confidence in their vision. The expertise of the founding team, combined with groundbreaking research from Stanford University, positions TwoStep Therapeutics at the forefront of next-generation cancer therapies. This launch represents a promising advancement in the fight against solid tumors, potentially transforming treatment options for many patients.
